open access
Omalizumab, recombinant humanized monoclonal antibody anti-IgE - new fields of studies on the therapeutic indications
open access
Abstract
Abstract
Keywords
omalizumab; atopic diseases; allergic rhinitis; atopic dermatitis; urticaria


Title
Omalizumab, recombinant humanized monoclonal antibody anti-IgE - new fields of studies on the therapeutic indications
Journal
Advances in Respiratory Medicine
Issue
Article type
Review paper
Pages
43-51
Published online
2008-12-19
Bibliographic record
Pneumonol Alergol Pol 2009;77(1):43-51.
Keywords
omalizumab
atopic diseases
allergic rhinitis
atopic dermatitis
urticaria
Authors
Izabela Kupryś-Lipińska
Piotr Kuna


- Kupryś I, Kuna P. [Regulation of immunoglobulin E synthesis]. Postepy Hig Med Dosw. 1997; 51(6): 651–682.
- Bozelka BE, McCants ML, Salvaggio JE, et al. IgE isotype suppression in anti-epsilon-treated mice. Immunology. 1982; 46(3): 527–532.
- Hamelmann E. The rationale for treating allergic asthma with anti-IgE. European Respiratory Review. 2007; 16(104): 61–66.
- Bobrowska M, Stelmach I. [Therapeutic possibilities and clinical effects of IgE level modulation in allergic diseases]. Pneumonol Alergol Pol. 2004; 72(1-2): 70–74.
- Sarinho E, Cruz AA. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases. J Pediatr (Rio J). 2006; 82(5 Suppl): S127–S132.
- Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170(6): 583–593.
- MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158(3): 1438–1445.
- Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004; 113(2): 297–302.
- Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol. 2006; 117(6): 1203–1212.
- Saini SS, MacGlashan DW, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999; 162(9): 5624–5630.
- Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003; 112(6): 1147–1154.
- Noga O, Hanf G, Kunkel G, et al. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol. 2008; 146(1): 66–70.
- Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006; 117(6): 1493–1499.
- Charakterystyka produktu leczniczego Xolair. www.novartis.pl.
- Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005; 60(3): 302–308.
- Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2004(3): CD003559.
- Chipps B, Buhl R, Beeh KM, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin. 2006; 22(11): 2201–2208.
- Casale TB, Condemi J, LaForce C, et al. Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001; 286(23): 2956–2967.
- Ogino S, Nagakura T, Okubo K, et al. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006; 55(4): 379–386.
- Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003; 91(2): 160–167.
- Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004; 59(7): 709–717.
- Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005; 53(2): 338–340.
- Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006; 54(1): 68–72.
- Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006; 55(1): 168–170.
- Forman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis. 2007; 80(1): 38–40.
- Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007; 120(5): 1223–1225.
- Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007; 99(2): 190–193.
- Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006; 117(6): 1415–1418.
- Metz M, Bergmann P, Zuberbier T, et al. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008; 63(2): 247–249.
- Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007; 120(4): 979–981.
- Leung DYM, Sampson HA, Yunginger JW, et al. Avon Longitudinal Study of Parents and Children Study Team. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003; 348(11): 986–993.
- Chang TW, Wu PC, Hsu CL, et al. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol. 2007; 93: 63–119.
- Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol. 2004; 113(2): 360–361.
- van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax. 2007; 62(3): 276–277.
- Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007; 119(6): 1550–1551.
- Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, et al. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007; 144(2): 155–158.
- Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med. 2006; 355(12): 1281–1282.
- Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol. 2008; 121(1): 253–254.
- Bargagli E, Madioni C, Olivieri C, et al. Churg-Strauss vasculitis in a patient treated with omalizumab. J Asthma. 2008; 45(2): 115–116.
- Lee J, Doggweiler-Wiygul R, Kim S, et al. Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE. Int J Urol. 2006; 13(5): 631–634.
- Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109(2): 274–280.
- Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. Omalizumab Rhinitis Study Group. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004; 59(9): 973–979.
- Kopp MV, Brauburger J, Riedinger F, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 110(5): 728–735.
- Kopp MV, Mayatepek E, Engels E, et al. Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab). Pediatr Allergy Immunol. 2003; 14(5): 401–404.
- Bez C, Schubert R, Kopp M, et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2004; 34(7): 1079–1085.
- Kopp MV, Stenglein S, Kamin W, et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol. 2007; 18(6): 523–527.
- Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006; 117(1): 134–140.
- Klunker S, Saggar LR, Seyfert-Margolis V, et al. Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007; 120(3): 688–695.
- Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy. 2007; 62(8): 963–964.
- Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy. 2008; 63(3): 376–378.
- Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol. 2008; 18(3): 225–226.
- Limb SL, Starke PR, Lee CE, et al. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007; 120(6): 1378–1381.
- Cox L, Platts-Mills TAE, Finegold I, et al. American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007; 120(6): 1373–1377.
- Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006; 96(4): 624–627.
- Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007; 28(3): 313–319.